Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. Its lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. TTI-0102 has been developed to address the obstacles facing previous thiol-based drugs, their short half-lives and side effects. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism that eliminates the spike in the immediate release of cysteamine that is commonly linked to GI side effects. TTI-0102â€™s initial applications are for mitochondrial encephalopathy, lactic acidosis and stroke-like episodes, Leigh syndrome, Rett syndrome and pediatric Nonalcoholic steatohepatitis.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
24/08/26	CA$0.5100	0.00%	13,500
21/08/26	CA$0.5100	+2.00%	30,000
20/08/26	CA$0.5000	-9.09%	205,666

Delayed Quote Toronto S.E.

More quotes

Net sales - Rate of surprise

Company calendar

Market Closed - Toronto S.E. 15:58:34 24/08/2026 BST			5-day change	1st Jan Change
0.5100 ^CAD	0.00%		0.00%	-21.54%

08-06	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-13	Thiogenesis Therapeutics Receives Fda Rare Pediatric Disease Designation for Tti-0102 for the Treatment of Leigh Syndrome	CI

Market Cap	35.69M 25.69M 22.13M 20.75M 18.95M 2.46B 35.8M 246M 96.07M 1.24B 96.44M 94.34M 4.11B	P/E 2024	-8.65x	P/E 2025	-4.25x
Enterprise Value	34.07M 24.52M 21.13M 19.81M 18.09M 2.34B 34.18M 235M 91.72M 1.18B 92.08M 90.07M 3.92B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	85.91%	Yield 2024 *	-	Yield 2025	-

08-06	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-13	Thiogenesis Therapeutics Receives Fda Rare Pediatric Disease Designation for Tti-0102 for the Treatment of Leigh Syndrome	CI
07-13	Thiogenesis Therapeutics' Treatment For Leigh Syndrome Receives FDA Rare Pediatric Disease Designation	MT
06-17	Thiogenesis Therapeutics Appoints Gilad Aharon to its Board	MT
06-17	Thiogenesis Therapeutics, Corp. Appoints Gilad Aharon to Its Board of Directors	CI
06-03	Thiogenesis Therapeutics, Corp. announced that it has received CAD 9.07185 million in funding	CI
05-25	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-11	Thiogenesis Therapeutics to Raise $8 Million Via a Non-Brokered Private Placement	MT
05-11	Thiogenesis Therapeutics, Corp. announced that it expects to receive CAD 8 million in funding	CI
04-30	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-29	Thiogenesis Therapeutics, Corp. Auditor Raises 'Going Concern' Doubt	CI
02-02	Thiogenesis Therapeutics, Corp. Provides Program Update	CI
01-23	Thiogenesis Therapeutics, Corp. Announces the Presentation of Interim Data from Its Phase 2 (Eu) Clinical Study of Tti-0102 in Patients with Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes At Mitocon 2026	CI

07-13	Thiogenesis Receives FDA Rare Pediatric Disease Designation for TTI-0102 for the Treatment of Leigh Syndrome	NE
06-17	Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors	NE
06-03	Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 Million	NE
06-01	Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares	NE
05-11	Thiogenesis Announces Non-Brokered Private Placement	NE

Thiogenesis Therapeutics, Corp. Share Price

Stocks

TTI

CA88410L1022

Biotechnology & Medical Research

Valuation : Thiogenesis Therapeutics, Corp.

Chart: Thiogenesis Therapeutics, Corp.

Latest news : Thiogenesis Therapeutics, Corp.

Analysts' recommendations : Thiogenesis Therapeutics, Corp.

Press Releases : Thiogenesis Therapeutics, Corp.

Quotes and Performance

Price Extremes

Managers and Directors : Thiogenesis Therapeutics, Corp.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Net sales - Rate of surprise

Current month	-5.56%
1 month	-10.53%
3 months	-16.39%
6 months	-5.56%
Current year	-21.54%

1 week	0.51	0.52
1 month	0.5	0.58
Current year	0.44	0.66
1 year	0.44	0.81
3 years	0.44	1.06
5 years	0.38	1.06
10 years	0.38	1.06

Manager	Title	Age	Since
Patrice Rioux CEO	Chief Executive Officer	75	30/03/2022
Brook Riggins CEO	Chief Executive Officer	60	-

Director	Title	Age	Since
Christopher Starr CHM	Chairman	73	30/03/2022
Patrice Rioux BRD	Director/Board Member	75	30/03/2022
Brook Riggins BRD	Director/Board Member	60	02/05/2018

Date	Insider	Type	Main position	Quantity	% Market Cap.
01/06/26	W. Mullally	Sell	Director	150,000	0.2894%
11/09/25	W. Mullally	Option	Director	75,000	0.1702%
01/08/25	W. Mullally	Sell	Director	64,000	0.1453%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
THIOGENESIS THERAPEUTICS, CORP.	0.00%	0.00%	-32.89%	-27.14%	25.69M
LONZA GROUP AG	-0.78%	-1.42%	+2.49%	+22.78%	50.47B
REVOLUTION MEDICINES, INC.	-6.00%	-0.75%	+442.41%	+544.39%	44.56B
IQVIA HOLDINGS INC.	-0.24%	+0.74%	+38.69%	+18.02%	43.08B
BEONE MEDICINES AG	-1.55%	-2.07%	+23.08%	+81.47%	41.7B
CELLTRION, INC.	-0.31%	-0.83%	+16.15%	+51.42%	33.21B
MEDPACE HOLDINGS, INC.	-1.79%	-3.24%	+27.00%	+129.56%	16.77B
ASCENDIS PHARMA A/S	-0.58%	-2.12%	-	-	16.28B
EUROFINS SCIENTIFIC SE	-0.88%	-0.66%	+11.60%	+27.75%	14.58B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.66%	-1.25%	+78.59%	+46.66%	13.92B
Average	-1.38%	-1.68%	+67.46%	+99.43%	27.46B
Weighted average by Cap.	-1.70%	-1.06%	+95.70%	+133.61%

	2024	2025
Net sales	-	-
Net income	-3.15M -2.26M -1.95M -1.83M -1.67M -216M -3.16M -21.7M -8.47M -109M -8.5M -8.32M -362M	-7.43M -5.34M -4.61M -4.32M -3.94M -511M -7.45M -51.23M -19.99M -258M -20.07M -19.63M -855M
Net Debt	-3.85M -2.77M -2.39M -2.24M -2.04M -265M -3.86M -26.55M -10.36M -134M -10.4M -10.17M -443M	-1.62M -1.16M -1M -940K -858K -111M -1.62M -11.15M -4.35M -56.11M -4.37M -4.27M -186M